News Archive

TEDCO, Maryland’s economic engine for technology companies, announced a recent $200,000 Pre-Seed Builder Funds investment in PerVista. Under the umbrella of TEDCO’s Social Impact Funds, the Pre-Seed Builder Fund invests in and provides support to Maryland-based technology companies led by founders

TEDCO, Maryland’s economic engine for technology companies, announces the panel “Reverse Engineering Your Exit: Growth with the End in Mind,” taking place during the upcoming 2025 Entrepreneur Expo. This year’s event will be held at The Hotel at the University of Maryland on October 21, 2025.

TEDCO, Maryland’s economic engine for technology companies, announces the panel “Investing in Maryland’s Future: SSBCI in Action,” taking place at the upcoming 2025 Entrepreneur Expo at The Hotel at the University of Maryland on October 21, 2025.

TEDCO, Maryland’s economic engine for technology companies, announced a recent $250,000 Pre-Seed Builder Fund investment in Natáur. The Pre-Seed Builder Fund is housed under the Social Impact Funds, an umbrella of investment opportunities that seek to provide eligible entrepreneurs with access to

TEDCO, Maryland's economic engine for technology companies, continues to uplift startup companies through its vast pool of resources and investment funds; recent investments include a $1.5M investment in Pixee along with investments in Atme, Astek Diagnostics, Higher Medicine, NanoBioFAB, TeamWorx

TEDCO, Maryland’s economic engine for technology companies, announced a recent Venture Funds investment in Zero Point Five Therapeutics. TEDCO’s evergreen Venture Funds are committed to investing in and advancing early-stage technology and life sciences companies across Maryland. These funds provide

TEDCO, Maryland's Economic Engine for technology companies, announces the selection of Collide Capital as one of the early-stage venture capital fund managers supporting the management and investment of up to $10 million in U.S. Department of Treasury State Small Business Credit Initiative (SSBCI)

ReBokeh app is now available at MIA for the 90% of people with vision impairment who retain functional vision. Miami International Airport has partnered with Baltimore-based software company ReBokeh Vision Technologies to launch free, unlimited access to ReBokeh’s empowerment-driven assistive

TEDCO, Maryland’s economic engine for technology companies, is pleased to announce the promotion of Jean-Luc Park to deputy chief investment officer and senior director, Social Impact Funds. In this role Park will be responsible for leading strategy and execution of investment activities focused on

To address the state’s emerging cybersecurity workforce demands, Cyber Maryland officially moved to the Maryland Department of Labor as of July 1, state officials announced.

The Cyber Maryland program, a workforce initiative focused on cybersecurity, artificial intelligence (AI), information technology, and related fields, has transitioned to the Maryland Department of Labor from the Maryland Technology Development Corporation (TEDCO), effective July 1, 2025. The move

Today's guest is Stephen Auvil, Chief Federal Engagement Officer at TEDCO, where he fosters connections and supports collaboration between industry and federal labs throughout Maryland. Stephen’s path began when an MBA class ignited his interest in combining science and business, shaping a career

Maryland's aerospace industry represents a formidable economic engine and a critical hub for national security and technological innovation. With 15 of the world’s top 20 aerospace and defense companies calling Maryland home, the state's capabilities span space exploration, satellite technology

Higher Medicine, located in Baltimore, Md., is a company working to develop functional cures for Kabuki syndrome (KS) using epigenetic modifying molecules. The business aims to restore the open versus closed chromatin balance, the primary cause of KS, by using an LSD-1 inhibitor and accelerating

Higher Medicine is a company working to develop functional cures for Kabuki syndrome (KS) using epigenetic modifying molecules. The business aims to restore the open versus closed chromatin balance, the primary cause of KS, by using an LSD-1 inhibitor and accelerating into a patient clinical study.